BioMarin climbs on rumors it may be Sanofi's Medivation backup

BioMarin

Sanofi is pushing full steam ahead with its hostile takeover try for Medivation. But rumor has it the California drugmaker may not be the only one on its target list.

Shares of rare-disease drugmaker BioMarin climbed Friday morning on speculation that that the French pharma giant could be zeroing in on it as a backup plan. At least, that’s the word from the Betaville blog, whose sources say Sanofi is growing weary of Medivation’s staunch resistance to its $52.50-per-share offer.

Of course, it’s all just buzz at this point, and as industry watchers know, buzz often amounts to nothing--especially where BioMarin is concerned. Last March, Betaville reported on a potential $65-billion Shire buyout of the San Rafael, California-based company that never came to fruition. And in 2013, the BioMarin takeover chatter was all centered on Roche, which reportedly was eyeing a $13.5 billion transaction.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Things are a little different now, though, as Betaville points out. BioMarin, like many of its biotech peers, has seen its shares fall on hard times, declining from a high near $150 last summer to just above $80 at Thursday’s close.

Sanofi, though, may have its priorities elsewhere. When laying out turnaround plans for the company early last November, new CEO Olivier Brandicourt outlined the areas where he already considered the company a market leader—rare diseases among them. Oncology, on the other hand, represented a business that needed bulking up to claim a spot in the top ranks, he said.

And that’s what a Medivation deal would do for Sanofi, which earlier this week dispatched ballots to Medivation shareholders in an attempt to wipe clean its slate of directors. The San Francisco drugmaker boasts high-flying prostate cancer pill Xtandi, a product that’s reportedly helped it draw interest from other Big Pharma players including Pfizer, Novartis and AstraZeneca.

- read the Betaville post 

Special Reports: The top 15 pharma comapnies by 2014 revenue - SanofiTop 15 Drug Launch Superstars - Xtandi - Medivation and Astellas Pharma 

Related Articles:
Sanofi and buyout target Medivation issue warring ballots as board fight officially begins
Most-wanted buyout target Medivation and hostile bidder Sanofi line up for board fight
Sanofi may spark a Medivation bidding war with $9.3B bid
Sanofi puts 2 units on the block, commits to $1.6B in cuts to turn business around​
BioMarin shares climb on Shire takeover buzz​
Roche chief tamps down talk of $13.5B BioMarin buyout

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.